Jounce Therapeutics, Inc., a Cambridge, MA-based clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, priced its initial public offering of 6,365,000 shares of common stock at a public offering price of $16.00 per share. for aggregate gross proceeds of $101.84m.
In addition, the company granted the underwriters a 30-day option to purchase up to 954,750 additional shares of its common stock at the initial public offering price.
The shares are scheduled to begin trading on The NASDAQ Global Select Market on January 27, 2017 under the ticker symbol “JNCE.”
Led by Richard Murray, PH.D., Chief Executive Officer and President, Jounce Therapeutics is a clinical stage immunotherapy company developing therapies that enable the immune system to attack. Jounce leverages its Translational Science Platform to focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
Launched in 2013 with funding from life sciences investor Third Rock Ventures, Jounce announced a global strategic collaboration with Celgene Corporation in July 2016.